Cargando…

FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells

SIMPLE SUMMARY: We created colorectal cancer in vitro models to study how an induced drug resistance profile can alter cell response and sensitivity to a treatment. By chronically exposing the cells to current first-line treatments (5-FU+folinic acid+oxaliplatin+SN38), resistance to the chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramzy, George M., Boschung, Laura, Koessler, Thibaud, Delucinge-Vivier, Céline, Docquier, Mylène, McKee, Thomas A., Rubbia-Brandt, Laura, Nowak-Sliwinska, Patrycja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564076/ https://www.ncbi.nlm.nih.gov/pubmed/36230735 http://dx.doi.org/10.3390/cancers14194812

Ejemplares similares

Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma
por: Ramzy, George M., et al.
Publicado: (2020)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
por: Rausch, Magdalena, et al.
Publicado: (2021)

Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma
por: Ramzy, George M., et al.
Publicado: (2023)

Optimized low‐dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma
por: Rausch, Magdalena, et al.
Publicado: (2021)

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer
por: Huy, Trinh Le, et al.
Publicado: (2019)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

FOLFOXIRI in Pregnant Women with Colorectal Cancer: A Case Report and Review of the Literature
por: Kozai, Landon, et al.
Publicado: (2022)

Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib
por: Berndsen, Robert H., et al.
Publicado: (2019)

FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
por: Antoniotti, Carlotta, et al.
Publicado: (2022)

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
por: Loupakis, F, et al.
Publicado: (2013)

Blockade of T Cell Contact-Activation of Human Monocytes by High-Density Lipoproteins Reveals a New Pattern of Cytokine and Inflammatory Genes
por: Gruaz, Lyssia, et al.
Publicado: (2010)

Erratum: Berndsen, R.H., et al. Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib, Cancers 2019, 11, 1878
por: Berndsen, Robert H., et al.
Publicado: (2020)

Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'
por: Bibeau, F, et al.
Publicado: (2013)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
por: Nowak-Sliwinska, Patrycja, et al.
Publicado: (2019)

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2011)

Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'
por: Schirripa, M, et al.
Publicado: (2013)

Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience
por: Kobayashi, Kazuma, et al.
Publicado: (2020)

FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
por: Lamarca, Angela, et al.
Publicado: (2020)

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature
por: Stein, Alexander, et al.
Publicado: (2012)

Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study
por: Ogata, Takatsugu, et al.
Publicado: (2019)

Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab
por: Li, Shenglin, et al.
Publicado: (2023)

Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review
por: Walter, H, et al.
Publicado: (2013)

Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy
por: Tamura, Nobumasa, et al.
Publicado: (2020)

Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma
por: Zoetemelk, Marloes, et al.
Publicado: (2019)

Where Are We Now and Where Might We Be Headed in Understanding and Managing Brain Metastases in Colorectal Cancer Patients?
por: Mjahed, Ribal Bou, et al.
Publicado: (2022)

Cohort profile: population-based cohorts of patients with colorectal cancer and of their relatives in Geneva, Switzerland
por: Benhamou, Simone, et al.
Publicado: (2022)

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
por: García‐Alfonso, Pilar, et al.
Publicado: (2018)

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
por: Rossini, Daniele, et al.
Publicado: (2020)

A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI)
por: Shinozaki, Katsunori, et al.
Publicado: (2020)

Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis
por: Chitikova, Zhanna, et al.
Publicado: (2015)

Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma
por: Makhlouf, Anne-Marie, et al.
Publicado: (2016)

A Patient with Transverse Colon Cancer Complicated by Cowden Syndrome Administered FOLFOXIRI + Bevacizumab Therapy
por: Takehara, Kazuhiro, et al.
Publicado: (2023)

FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer
por: Cervantes, A., et al.
Publicado: (2023)

Apoptosis on the move
por: Nowak-Sliwinska, Patrycja, et al.
Publicado: (2018)

Programmed cell death lives
por: Griffioen, Arjan W., et al.
Publicado: (2022)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
por: Folprecht, Gunnar, et al.
Publicado: (2014)

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qduf2aabq9jaihf78kbtnt981m